The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors ...

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at ...

(Reuters) -Pfizer Inc said on Monday it has filed a second lawsuit against Metsera and its controlling shareholders, as well ...

The start of a traditionally solid month on Wall Street saw stocks rising as Amazon.com Inc.’s $38 billion deal with OpenAI ...

The US pharma giant wants a court to stop biotech Metsera from ditching its deal for an $8.5 bln rival bid from Novo Nordisk. The Danish giant's cash comes with few strings, making the legal approach ...

George Tidmarsh denied wrongdoing at the FDA and accused senior FDA officials — including CBER chief Vinay Prasad — of wrongdoing ...

The FDA's top regulator of medicines has resigned after being accused of using his regulatory authority to harm a former ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

Pfizer filed its second lawsuit against Metsera and Novo Nordisk, alleging Novo Nordisk's attempt to outbid Pfizer to acquire Metsera violates antitrust laws.

A key part of the president’s trade policy faces scrutiny by the Supreme Court this week, with huge implications for business.

Lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing ...